DEVELOPMENT & IMPLEMENTATION OF THE MAT THE NBI EXPERIENCE

Jaclyn Scheepers - Specialist Scientist Cell Biology



Committed to providing safe, cost effective, quality medicinal products.



AGENDA

- Introduction
- Pyrogen Testing at NBI
- Development of the MAT
- Validation
- Implementation
- Challenges



COMPANY OVERVIEW





NBI is a private, non-profit, pharmaceutical company that manufactures plasma-derived medicinal products (PDMPs) from fresh/frozen plasma of human origin, using the process of cold ethanol fractionation. Our products are marketed, sold and distributed to reach South and Southern African patients.


The company's manufacturing site and head office are located in Pinetown, KwaZulu-Natal, South Africa.

Overview of NBI's Product Range


Pharmaceuticals (PDMPs)



Diagnostics




Compliance with Local and International Regulatory Requirements





WHO Technical Report series

MAT TESTING OF NBI PRODUCTS



Why develop an in-house MAT when off the shelf kits are available?

WHY DEVELOP A MAT WHEN THERE ARE COMMERCIAL MAT KITS AVAILABLE?

Cost





Delivery Time

Regulatory Red Tape





In-house Capability

DEVELOPMENT OF THE NBI MAT



1. Monocyte Activation(Immunological Response)




Cell Source



2. ELISA



Interleukin Detection



3. Analysis

(Quantification of pyrogenic contamination)


Cell Source

- Cryopreserved PBMCs
- Pool of 4 donors
- Donors group of NBI volunteers
- South African National Blood Service (SANBS) assists with blood draw
- Density gradient isolation
- Long-term storage —liquid nitrogen vapour phase
- Qualification of cryopreserved pool

Challenges

- Technical expertise
- Labour intensive
- Processing time
- Facility capacity/capabilities (e.g. centrifugation; rate-controlled freezing)









Qualification of Cryopreserved PBMCs

Pooling of PBMCs from 4 donors overcomes donor variability




Non-endotoxin detection



- Peptidoglycan (PGN)
- Flagellin (FLA)

Interleukin Detection

- PBMCs respond to endotoxin & NEPs by releasing pro-inflammatory cytokines e.g. Interleukin-6 (IL-6), IL-1β or tumour necrosis factor (TNF)
- IL-6 shown to have higher sensitivity
- Opted for commercial IL-6 ELISA & adapted it for use in the NBI-MAT





Product Specific Validations

Interference Testing



Endotoxin International Standard

Detection of NEPs

• PGN

Interference in the Detection System

Submission to Regulator



- All PDMPs except for 1 tested using Method 1 (previously known as Method A)
- 1x PDMP tested using Method 2 (previously know as Method C)

Implementation

- Regulatory Approval SAHPRA
- Training of QC Analyst
 - Theory
 - Hands-on Practical
 - Competency
- Setup & equipping of testing laboratory







Challenges

Technical

- PBMC processing
- Technically challenging assay requires excellent pipetting skills and knowledge of cell culture and proper handling of cells
- Method 1 is more technically demanding, however, we have had more issues with the implementation of Method 2 but we are currently working on this

Training

- 7-8 months, ideally more is required
- Critical that analysts are not only capable of performing the MAT but that they have an excellent theoretical understanding of the assay and knowledge of why certain steps are performed the way that they are.

Laboratory Facilities & Equipment

- PBMCs centrifugation capacity, rate-controlled freezer/containers, liquid nitrogen vapour phase storage
- Performing the MAT
 - Ergonomic Pipettes Reduce Repetitive Stress Injuries
 - Good quality, compatible pipette tips for accuracy

Products

1x product that is particularly challenging – significant interference with the MAT



Thank You

NATIONAL BIOPRODUCTS INSTITUTE NPC

www.nbisa.org.za